Abstract
Alzheimers Disease (AD) physiopathology is not yet totally established. Nevertheless it is known that a metabolism dysfunction of the amyloid beta precursor protein (APP) and the abnormal tau protein phosphorylation lead to the formation of neuritic plaques and neurofibrillary tangles, respectively. These events finally drive to the clinical expression of dementia. Formally approved during the past decade, treatments for AD are lacking of an updating, being essentially symptomatic. Anticholinesterase agents have failed in providing a substantial improvement in the mental health condition of AD patients. On the other hand, antiamyloid strategies, have failed in their efficacy or security on their last development phases. In this context, tau represents a potential therapeutic target, by the action of drugs that diminish its aggregation, or acting by altering its phosphorylation or filaments formation. There is also anti-tau miscellaneous strategies such as normal microtubule-stabilizing agents. Thus, it might be possible that in a near future the neurodegenerative process could be stopped.
Keywords: Alzheimer's disease, disease tratement avenues, tau protein, anti-tau agents, tau pathology, clinical correlations, donepezil, NMDA receptor, ChEIs, 3xTg-AD, intracellular proteins, sequestration, NAP, ICC, GSK-3, CLK-2, HEB, polyubiquitinate tau
Current Alzheimer Research
Title: A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease
Volume: 8 Issue: 6
Author(s): P. Fuentes and J. Catalan
Affiliation:
Keywords: Alzheimer's disease, disease tratement avenues, tau protein, anti-tau agents, tau pathology, clinical correlations, donepezil, NMDA receptor, ChEIs, 3xTg-AD, intracellular proteins, sequestration, NAP, ICC, GSK-3, CLK-2, HEB, polyubiquitinate tau
Abstract: Alzheimers Disease (AD) physiopathology is not yet totally established. Nevertheless it is known that a metabolism dysfunction of the amyloid beta precursor protein (APP) and the abnormal tau protein phosphorylation lead to the formation of neuritic plaques and neurofibrillary tangles, respectively. These events finally drive to the clinical expression of dementia. Formally approved during the past decade, treatments for AD are lacking of an updating, being essentially symptomatic. Anticholinesterase agents have failed in providing a substantial improvement in the mental health condition of AD patients. On the other hand, antiamyloid strategies, have failed in their efficacy or security on their last development phases. In this context, tau represents a potential therapeutic target, by the action of drugs that diminish its aggregation, or acting by altering its phosphorylation or filaments formation. There is also anti-tau miscellaneous strategies such as normal microtubule-stabilizing agents. Thus, it might be possible that in a near future the neurodegenerative process could be stopped.
Export Options
About this article
Cite this article as:
Fuentes P. and Catalan J., A Clinical Perspective: Anti Taus Treatment in Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717221
DOI https://dx.doi.org/10.2174/156720511796717221 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent
Current Drug Safety Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders
Current Alzheimer Research Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review
Current Clinical Pharmacology Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines
Current Alzheimer Research Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Elucidating Neuronal and Vascular Injury Through the Cytoprotective Agent Nicotinamide
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease
Current Medical Imaging Contraindications for Anticoagulation in Older Patients with Atrial Fibrillation: A Narrative Review
Current Drug Safety Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Hypoxia, Lead Toxicities and Oxidative Stress: Cell Signaling, Molecular Interactions and Antioxidant (Vitamin C) Defense
Current Signal Transduction Therapy Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Pharmacophore Based 3DQSAR of Phenothiazines as Specific Human Butyrylcholinesterase Inhibitors for Treatment of Alzheimer’s Disease
Current Computer-Aided Drug Design The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Threshold-Independent Meta-Analysis of Alzheimer`s Disease Transcriptomes shows Progressive Changes in Hippocampal Functions, Epigenetics and microRNA Regulation
Current Alzheimer Research Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design Cardiovascular Drugs and Bone
Current Drug Safety